Affimed SG&A Expenses 2014-2024 | AFMDQ
Affimed sg&a expenses from 2014 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Affimed Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$27 |
| 2022 |
$34 |
| 2021 |
$29 |
| 2020 |
$16 |
| 2019 |
$11 |
| 2018 |
$11 |
| 2017 |
$9 |
| 2016 |
$9 |
| 2015 |
$8 |
| 2014 |
$3 |
| 2013 |
$0 |
| 2012 |
$0 |
Affimed Quarterly SG&A Expenses
(Millions of US $) |
| 2024-09-30 |
$5 |
| 2024-06-30 |
$4 |
| 2024-03-31 |
$5 |
| 2023-12-31 |
$7 |
| 2023-09-30 |
$6 |
| 2023-06-30 |
$7 |
| 2023-03-31 |
$7 |
| 2022-12-31 |
$9 |
| 2022-09-30 |
$8 |
| 2022-06-30 |
$9 |
| 2022-03-31 |
$8 |
| 2021-12-31 |
$9 |
| 2021-09-30 |
$8 |
| 2021-06-30 |
$7 |
| 2021-03-31 |
$5 |
| 2020-12-31 |
$5 |
| 2020-09-30 |
$4 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$4 |
| 2019-12-31 |
$3 |
| 2019-09-30 |
$3 |
| 2019-06-30 |
$3 |
| 2019-03-31 |
$3 |
| 2018-12-31 |
$4 |
| 2018-09-30 |
$3 |
| 2018-06-30 |
$3 |
| 2018-03-31 |
$3 |
| 2017-12-31 |
$2 |
| 2017-09-30 |
$2 |
| 2017-06-30 |
$2 |
| 2017-03-31 |
$2 |
| 2016-12-31 |
$2 |
| 2016-09-30 |
$2 |
| 2016-06-30 |
$2 |
| 2016-03-31 |
$2 |
| 2015-12-31 |
$2 |
| 2015-09-30 |
$2 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$2 |
| 2014-12-31 |
|
| 2014-09-30 |
$0 |
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-09-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
